[
{
"old_id":"1",
"old_nametree":"Authors and legal information",
"old_numtree":"1.0.0.0",
"old_htmlpage":"ENAS5281_1.0.0.0",
"new_id":"1",
"new_nametree":"Authors and legal information",
"new_numtree":"1.0.0.0",
"new_htmlpage":"ENAS5281_1.0.0.0"
},
{
"old_id":"2",
"old_nametree":"Dx and personalised medicine",
"old_numtree":"2.0.0.0",
"old_htmlpage":"null",
"new_id":"2",
"new_nametree":"Dx and personalised medicine",
"new_numtree":"2.0.0.0",
"new_htmlpage":"null"
},
{
"old_id":"3",
"old_nametree":"Overview",
"old_numtree":"2.1.0.0",
"old_htmlpage":"ENAS5281_2.1.0.0",
"new_id":"3",
"new_nametree":"Overview",
"new_numtree":"2.1.0.0",
"new_htmlpage":"ENAS5281_2.1.0.0"
},
{
"old_id":"4",
"old_nametree":"A personalised medicine synopsis",
"old_numtree":"2.2.0.0",
"old_htmlpage":"ENAS5281_2.2.0.0",
"new_id":"4",
"new_nametree":"A personalised medicine synopsis",
"new_numtree":"2.2.0.0",
"new_htmlpage":"ENAS5281_2.2.0.0"
},
{
"old_id":"5",
"old_nametree":"Staging and risk assessment",
"old_numtree":"3.0.0.0",
"old_htmlpage":"null",
"new_id":"5",
"new_nametree":"Staging and risk assessment",
"new_numtree":"3.0.0.0",
"new_htmlpage":"null"
},
{
"old_id":"6",
"old_nametree":"Overview",
"old_numtree":"3.1.0.0",
"old_htmlpage":"ENAS5281_3.1.0.0",
"new_id":"6",
"new_nametree":"Overview",
"new_numtree":"3.1.0.0",
"new_htmlpage":"ENAS5281_3.1.0.0"
},
{
"old_id":"7",
"old_nametree":"TNM staging",
"old_numtree":"3.2.0.0",
"old_htmlpage":"ENAS5281_3.2.0.0",
"new_id":"7",
"new_nametree":"TNM staging",
"new_numtree":"3.2.0.0",
"new_htmlpage":"ENAS5281_3.2.0.0"
},
{
"old_id":"8",
"old_nametree":"Anatomic stage/ prognostic groups",
"old_numtree":"3.3.0.0",
"old_htmlpage":"ENAS5281_3.3.0.0",
"new_id":"8",
"new_nametree":"Anatomic stage/ prognostic groups",
"new_numtree":"3.3.0.0",
"new_htmlpage":"ENAS5281_3.3.0.0"
},
{
"old_id":"9",
"old_nametree":"Mgmt. of advanced/ metastatic disease",
"old_numtree":"4.0.0.0",
"old_htmlpage":"null",
"new_id":"9",
"new_nametree":"Mgmt. of advanced/ metastatic disease",
"new_numtree":"4.0.0.0",
"new_htmlpage":"null"
},
{
"old_id":"10",
"old_nametree":"Overview",
"old_numtree":"4.1.0.0",
"old_htmlpage":"ENAS5281_4.1.0.0",
"new_id":"10",
"new_nametree":"Overview",
"new_numtree":"4.1.0.0",
"new_htmlpage":"ENAS5281_4.1.0.0"
},
{
"old_id":"11",
"old_nametree":"Mgmt. algo. for stage IV SCC and NSCC",
"old_numtree":"4.2.0.0",
"old_htmlpage":"null",
"new_id":"11",
"new_nametree":"Mgmt. algo. for stage IV SCC and NSCC",
"new_numtree":"4.2.0.0",
"new_htmlpage":"null"
},
{
"old_id":"12",
"old_nametree":"Treatment for stage IV SCC",
"old_numtree":"4.2.1.0",
"old_htmlpage":"ENAS5281_4.2.1.0",
"new_id":"12",
"new_nametree":"Treatment for stage IV SCC",
"new_numtree":"4.2.1.0",
"new_htmlpage":"ENAS5281_4.2.1.0"
},
{
"old_id":"13",
"old_nametree":"Treatment for stage IV NSCC",
"old_numtree":"4.2.2.0",
"old_htmlpage":"ENAS5281_4.2.2.0",
"new_id":"13",
"new_nametree":"Treatment for stage IV NSCC",
"new_numtree":"4.2.2.0",
"new_htmlpage":"ENAS5281_4.2.2.0"
},
{
"old_id":"14",
"old_nametree":"First-line treatment",
"old_numtree":"4.3.0.0",
"old_htmlpage":"null",
"new_id":"14",
"new_nametree":"First-line treatment",
"new_numtree":"4.3.0.0",
"new_htmlpage":"null"
},
{
"old_id":"15",
"old_nametree":"EGFR- and ALK-negative disease",
"old_numtree":"4.3.1.0",
"old_htmlpage":"ENAS5281_4.3.1.0",
"new_id":"15",
"new_nametree":"EGFR- and ALK-negative disease",
"new_numtree":"4.3.1.0",
"new_htmlpage":"ENAS5281_4.3.1.0"
},
{
"old_id":"16",
"old_nametree":"SCC",
"old_numtree":"4.3.2.0",
"old_htmlpage":"ENAS5281_4.3.2.0",
"new_id":"16",
"new_nametree":"SCC",
"new_numtree":"4.3.2.0",
"new_htmlpage":"ENAS5281_4.3.2.0"
},
{
"old_id":"17",
"old_nametree":"NSCC",
"old_numtree":"4.3.3.0",
"old_htmlpage":"ENAS5281_4.3.3.0",
"new_id":"17",
"new_nametree":"NSCC",
"new_numtree":"4.3.3.0",
"new_htmlpage":"ENAS5281_4.3.3.0"
},
{
"old_id":"18",
"old_nametree":"PS 2 and beyond",
"old_numtree":"4.4.0.0",
"old_htmlpage":"ENAS5281_4.4.0.0",
"new_id":"18",
"new_nametree":"PS 2 and beyond",
"new_numtree":"4.4.0.0",
"new_htmlpage":"ENAS5281_4.4.0.0"
},
{
"old_id":"19",
"old_nametree":"Elderly patients",
"old_numtree":"4.5.0.0",
"old_htmlpage":"ENAS5281_4.5.0.0",
"new_id":"19",
"new_nametree":"Elderly patients",
"new_numtree":"4.5.0.0",
"new_htmlpage":"ENAS5281_4.5.0.0"
},
{
"old_id":"20",
"old_nametree":"Maintenance",
"old_numtree":"4.6.0.0",
"old_htmlpage":"ENAS5281_4.6.0.0",
"new_id":"20",
"new_nametree":"Maintenance",
"new_numtree":"4.6.0.0",
"new_htmlpage":"ENAS5281_4.6.0.0"
},
{
"old_id":"21",
"old_nametree":"Second-line Tx",
"old_numtree":"4.7.0.0",
"old_htmlpage":"null",
"new_id":"21",
"new_nametree":"Second-line Tx",
"new_numtree":"4.7.0.0",
"new_htmlpage":"null"
},
{
"old_id":"22",
"old_nametree":"EGFR- and ALK-negative disease",
"old_numtree":"4.7.1.0",
"old_htmlpage":"ENAS5281_4.7.1.0",
"new_id":"22",
"new_nametree":"EGFR- and ALK-negative disease",
"new_numtree":"4.7.1.0",
"new_htmlpage":"ENAS5281_4.7.1.0"
},
{
"old_id":"23",
"old_nametree":"SCC",
"old_numtree":"4.7.2.0",
"old_htmlpage":"ENAS5281_4.7.2.0",
"new_id":"23",
"new_nametree":"SCC",
"new_numtree":"4.7.2.0",
"new_htmlpage":"ENAS5281_4.7.2.0"
},
{
"old_id":"24",
"old_nametree":"NSCC",
"old_numtree":"4.7.3.0",
"old_htmlpage":"ENAS5281_4.7.3.0",
"new_id":"24",
"new_nametree":"NSCC",
"new_numtree":"4.7.3.0",
"new_htmlpage":"ENAS5281_4.7.3.0"
},
{
"old_id":"25",
"old_nametree":"EGFR-mutated NSCLC pts",
"old_numtree":"4.8.0.0",
"old_htmlpage":"null",
"new_id":"25",
"new_nametree":"EGFR-mutated NSCLC pts",
"new_numtree":"4.8.0.0",
"new_htmlpage":"null"
},
{
"old_id":"26",
"old_nametree":"Overview",
"old_numtree":"4.8.1.0",
"old_htmlpage":"ENAS5281_4.8.1.0",
"new_id":"26",
"new_nametree":"Overview",
"new_numtree":"4.8.1.0",
"new_htmlpage":"ENAS5281_4.8.1.0"
},
{
"old_id":"27",
"old_nametree":"Tx for IIIB–IV w/ EGFR mutation",
"old_numtree":"4.8.2.0",
"old_htmlpage":"ENAS5281_4.8.2.0",
"new_id":"27",
"new_nametree":"Tx for IIIB–IV w/ EGFR mutation",
"new_numtree":"4.8.2.0",
"new_htmlpage":"ENAS5281_4.8.2.0"
},
{
"old_id":"28",
"old_nametree":"ALK-rearranged NSCLC patients",
"old_numtree":"4.9.0.0",
"old_htmlpage":"null",
"new_id":"28",
"new_nametree":"ALK-rearranged NSCLC patients",
"new_numtree":"4.9.0.0",
"new_htmlpage":"null"
},
{
"old_id":"29",
"old_nametree":"Overview",
"old_numtree":"4.9.1.0",
"old_htmlpage":"ENAS5281_4.9.1.0",
"new_id":"29",
"new_nametree":"Overview",
"new_numtree":"4.9.1.0",
"new_htmlpage":"ENAS5281_4.9.1.0"
},
{
"old_id":"30",
"old_nametree":"Tx for IIIB-IV w/ ALK translocation",
"old_numtree":"4.9.2.0",
"old_htmlpage":"ENAS5281_4.9.2.0",
"new_id":"30",
"new_nametree":"Tx for IIIB-IV w/ ALK translocation",
"new_numtree":"4.9.2.0",
"new_htmlpage":"ENAS5281_4.9.2.0"
},
{
"old_id":"31",
"old_nametree":"Role of RT in stage IV NSCLC",
"old_numtree":"4.10.0.0",
"old_htmlpage":"ENAS5281_4.10.0.0",
"new_id":"31",
"new_nametree":"Role of RT in stage IV NSCLC",
"new_numtree":"4.10.0.0",
"new_htmlpage":"ENAS5281_4.10.0.0"
},
{
"old_id":"32",
"old_nametree":"Palliative surgery in stage IV NSCLC",
"old_numtree":"4.11.0.0",
"old_htmlpage":"ENAS5281_4.11.0.0",
"new_id":"32",
"new_nametree":"Palliative surgery in stage IV NSCLC",
"new_numtree":"4.11.0.0",
"new_htmlpage":"ENAS5281_4.11.0.0"
},
{
"old_id":"33",
"old_nametree":"Minim.-invasive proce. in IV NSCLC",
"old_numtree":"4.12.0.0",
"old_htmlpage":"ENAS5281_4.12.0.0",
"new_id":"33",
"new_nametree":"Minim.-invasive proce. in IV NSCLC",
"new_numtree":"4.12.0.0",
"new_htmlpage":"ENAS5281_4.12.0.0"
},
{
"old_id":"34",
"old_nametree":"Role of palliative care in stage IV NSCLC",
"old_numtree":"4.13.0.0",
"old_htmlpage":"ENAS5281_4.13.0.0",
"new_id":"34",
"new_nametree":"Role of palliative care in stage IV NSCLC",
"new_numtree":"4.13.0.0",
"new_htmlpage":"ENAS5281_4.13.0.0"
},
{
"old_id":"35",
"old_nametree":"Focus on brain and bone metastases",
"old_numtree":"4.14.0.0",
"old_htmlpage":"null",
"new_id":"35",
"new_nametree":"Focus on brain and bone metastases",
"new_numtree":"4.14.0.0",
"new_htmlpage":"null"
},
{
"old_id":"36",
"old_nametree":"Brain metastases",
"old_numtree":"4.14.1.0",
"old_htmlpage":"ENAS5281_4.14.1.0",
"new_id":"36",
"new_nametree":"Brain metastases",
"new_numtree":"4.14.1.0",
"new_htmlpage":"ENAS5281_4.14.1.0"
},
{
"old_id":"37",
"old_nametree":"Bone metastases",
"old_numtree":"4.14.2.0",
"old_htmlpage":"ENAS5281_4.14.2.0",
"new_id":"37",
"new_nametree":"Bone metastases",
"new_numtree":"4.14.2.0",
"new_htmlpage":"ENAS5281_4.14.2.0"
},
{
"old_id":"38",
"old_nametree":"Tx of oligometastatic NSCLC",
"old_numtree":"4.15.0.0",
"old_htmlpage":"ENAS5281_4.15.0.0",
"new_id":"38",
"new_nametree":"Tx of oligometastatic NSCLC",
"new_numtree":"4.15.0.0",
"new_htmlpage":"ENAS5281_4.15.0.0"
},
{
"old_id":"39",
"old_nametree":"Response evaluation",
"old_numtree":"5.0.0.0",
"old_htmlpage":"ENAS5281_5.0.0.0",
"new_id":"39",
"new_nametree":"Response evaluation",
"new_numtree":"5.0.0.0",
"new_htmlpage":"ENAS5281_5.0.0.0"
},
{
"old_id":"40",
"old_nametree":"Follow-up",
"old_numtree":"6.0.0.0",
"old_htmlpage":"ENAS5281_6.0.0.0",
"new_id":"40",
"new_nametree":"Follow-up",
"new_numtree":"6.0.0.0",
"new_htmlpage":"ENAS5281_6.0.0.0"
},
{
"old_id":"41",
"old_nametree":"Summary of recommendations",
"old_numtree":"7.0.0.0",
"old_htmlpage":"null",
"new_id":"41",
"new_nametree":"Summary of recommendations",
"new_numtree":"7.0.0.0",
"new_htmlpage":"null"
},
{
"old_id":"42",
"old_nametree":"Dx and personalised medicine",
"old_numtree":"7.1.0.0",
"old_htmlpage":"ENAS5281_7.1.0.0",
"new_id":"42",
"new_nametree":"Dx and personalised medicine",
"new_numtree":"7.1.0.0",
"new_htmlpage":"ENAS5281_7.1.0.0"
},
{
"old_id":"43",
"old_nametree":"Staging and risk assessment",
"old_numtree":"7.2.0.0",
"old_htmlpage":"ENAS5281_7.2.0.0",
"new_id":"43",
"new_nametree":"Staging and risk assessment",
"new_numtree":"7.2.0.0",
"new_htmlpage":"ENAS5281_7.2.0.0"
},
{
"old_id":"44",
"old_nametree":"Mgmt. of advanced/ metastatic disease",
"old_numtree":"7.3.0.0",
"old_htmlpage":"null",
"new_id":"44",
"new_nametree":"Mgmt. of advanced/ metastatic disease",
"new_numtree":"7.3.0.0",
"new_htmlpage":"null"
},
{
"old_id":"45",
"old_nametree":"Overview",
"old_numtree":"7.3.1.0",
"old_htmlpage":"ENAS5281_7.3.1.0",
"new_id":"45",
"new_nametree":"Overview",
"new_numtree":"7.3.1.0",
"new_htmlpage":"ENAS5281_7.3.1.0"
},
{
"old_id":"46",
"old_nametree":"First-line treatment",
"old_numtree":"7.3.2.0",
"old_htmlpage":"null",
"new_id":"46",
"new_nametree":"First-line treatment",
"new_numtree":"7.3.2.0",
"new_htmlpage":"null"
},
{
"old_id":"47",
"old_nametree":"EGFR- and ALK-negative disease",
"old_numtree":"7.3.2.1",
"old_htmlpage":"ENAS5281_7.3.2.1",
"new_id":"47",
"new_nametree":"EGFR- and ALK-negative disease",
"new_numtree":"7.3.2.1",
"new_htmlpage":"ENAS5281_7.3.2.1"
},
{
"old_id":"48",
"old_nametree":"SCC",
"old_numtree":"7.3.2.2",
"old_htmlpage":"ENAS5281_7.3.2.2",
"new_id":"48",
"new_nametree":"SCC",
"new_numtree":"7.3.2.2",
"new_htmlpage":"ENAS5281_7.3.2.2"
},
{
"old_id":"49",
"old_nametree":"NSCC",
"old_numtree":"7.3.2.3",
"old_htmlpage":"ENAS5281_7.3.2.3",
"new_id":"49",
"new_nametree":"NSCC",
"new_numtree":"7.3.2.3",
"new_htmlpage":"ENAS5281_7.3.2.3"
},
{
"old_id":"50",
"old_nametree":"PS 2 and beyond",
"old_numtree":"7.3.3.0",
"old_htmlpage":"ENAS5281_7.3.3.0",
"new_id":"50",
"new_nametree":"PS 2 and beyond",
"new_numtree":"7.3.3.0",
"new_htmlpage":"ENAS5281_7.3.3.0"
},
{
"old_id":"51",
"old_nametree":"Elderly patients",
"old_numtree":"7.3.4.0",
"old_htmlpage":"ENAS5281_7.3.4.0",
"new_id":"51",
"new_nametree":"Elderly patients",
"new_numtree":"7.3.4.0",
"new_htmlpage":"ENAS5281_7.3.4.0"
},
{
"old_id":"52",
"old_nametree":"Maintenance",
"old_numtree":"7.3.5.0",
"old_htmlpage":"ENAS5281_7.3.5.0",
"new_id":"52",
"new_nametree":"Maintenance",
"new_numtree":"7.3.5.0",
"new_htmlpage":"ENAS5281_7.3.5.0"
},
{
"old_id":"53",
"old_nametree":"Second-line treatment",
"old_numtree":"7.3.6.0",
"old_htmlpage":"null",
"new_id":"53",
"new_nametree":"Second-line treatment",
"new_numtree":"7.3.6.0",
"new_htmlpage":"null"
},
{
"old_id":"54",
"old_nametree":"EGFR- and ALK-negative disease",
"old_numtree":"7.3.6.1",
"old_htmlpage":"ENAS5281_7.3.6.1",
"new_id":"54",
"new_nametree":"EGFR- and ALK-negative disease",
"new_numtree":"7.3.6.1",
"new_htmlpage":"ENAS5281_7.3.6.1"
},
{
"old_id":"55",
"old_nametree":"SCC",
"old_numtree":"7.3.6.2",
"old_htmlpage":"ENAS5281_7.3.6.2",
"new_id":"55",
"new_nametree":"SCC",
"new_numtree":"7.3.6.2",
"new_htmlpage":"ENAS5281_7.3.6.2"
},
{
"old_id":"56",
"old_nametree":"NSCC",
"old_numtree":"7.3.6.3",
"old_htmlpage":"ENAS5281_7.3.6.3",
"new_id":"56",
"new_nametree":"NSCC",
"new_numtree":"7.3.6.3",
"new_htmlpage":"ENAS5281_7.3.6.3"
},
{
"old_id":"57",
"old_nametree":"EGFR-mutated NSCLC patients",
"old_numtree":"7.3.7.0",
"old_htmlpage":"ENAS5281_7.3.7.0",
"new_id":"57",
"new_nametree":"EGFR-mutated NSCLC patients",
"new_numtree":"7.3.7.0",
"new_htmlpage":"ENAS5281_7.3.7.0"
},
{
"old_id":"58",
"old_nametree":"ALK-rearranged NSCLC patients",
"old_numtree":"7.3.8.0",
"old_htmlpage":"ENAS5281_7.3.8.0",
"new_id":"58",
"new_nametree":"ALK-rearranged NSCLC patients",
"new_numtree":"7.3.8.0",
"new_htmlpage":"ENAS5281_7.3.8.0"
},
{
"old_id":"59",
"old_nametree":"Role of RT in stage IV NSCLC",
"old_numtree":"7.3.9.0",
"old_htmlpage":"ENAS5281_7.3.9.0",
"new_id":"59",
"new_nametree":"Role of RT in stage IV NSCLC",
"new_numtree":"7.3.9.0",
"new_htmlpage":"ENAS5281_7.3.9.0"
},
{
"old_id":"60",
"old_nametree":"Palliative surgery in stage IV NSCLC",
"old_numtree":"7.3.10.0",
"old_htmlpage":"ENAS5281_7.3.10.0",
"new_id":"60",
"new_nametree":"Palliative surgery in stage IV NSCLC",
"new_numtree":"7.3.10.0",
"new_htmlpage":"ENAS5281_7.3.10.0"
},
{
"old_id":"61",
"old_nametree":"Minim.-invasive proce. in IV NSCLC",
"old_numtree":"7.3.11.0",
"old_htmlpage":"ENAS5281_7.3.11.0",
"new_id":"61",
"new_nametree":"Minim.-invasive proce. in IV NSCLC",
"new_numtree":"7.3.11.0",
"new_htmlpage":"ENAS5281_7.3.11.0"
},
{
"old_id":"62",
"old_nametree":"Role of palliative care in stage IV NSCLC",
"old_numtree":"7.3.12.0",
"old_htmlpage":"ENAS5281_7.3.12.0",
"new_id":"62",
"new_nametree":"Role of palliative care in stage IV NSCLC",
"new_numtree":"7.3.12.0",
"new_htmlpage":"ENAS5281_7.3.12.0"
},
{
"old_id":"63",
"old_nametree":"Focus on brain and bone metastases",
"old_numtree":"7.3.13.0",
"old_htmlpage":"null",
"new_id":"63",
"new_nametree":"Focus on brain and bone metastases",
"new_numtree":"7.3.13.0",
"new_htmlpage":"null"
},
{
"old_id":"64",
"old_nametree":"Brain metastases",
"old_numtree":"7.3.13.1",
"old_htmlpage":"ENAS5281_7.3.13.1",
"new_id":"64",
"new_nametree":"Brain metastases",
"new_numtree":"7.3.13.1",
"new_htmlpage":"ENAS5281_7.3.13.1"
},
{
"old_id":"65",
"old_nametree":"Bone metastases",
"old_numtree":"7.3.13.2",
"old_htmlpage":"ENAS5281_7.3.13.2",
"new_id":"65",
"new_nametree":"Bone metastases",
"new_numtree":"7.3.13.2",
"new_htmlpage":"ENAS5281_7.3.13.2"
},
{
"old_id":"66",
"old_nametree":"Treatment of oligometastatic NSCLC",
"old_numtree":"7.3.14.0",
"old_htmlpage":"ENAS5281_7.3.14.0",
"new_id":"66",
"new_nametree":"Treatment of oligometastatic NSCLC",
"new_numtree":"7.3.14.0",
"new_htmlpage":"ENAS5281_7.3.14.0"
},
{
"old_id":"67",
"old_nametree":"Response evaluation",
"old_numtree":"7.4.0.0",
"old_htmlpage":"ENAS5281_7.4.0.0",
"new_id":"67",
"new_nametree":"Response evaluation",
"new_numtree":"7.4.0.0",
"new_htmlpage":"ENAS5281_7.4.0.0"
},
{
"old_id":"68",
"old_nametree":"Follow-up",
"old_numtree":"7.5.0.0",
"old_htmlpage":"ENAS5281_7.5.0.0",
"new_id":"68",
"new_nametree":"Follow-up",
"new_numtree":"7.5.0.0",
"new_htmlpage":"ENAS5281_7.5.0.0"
},
{
"old_id":"69",
"old_nametree":"Glossary",
"old_numtree":"8.0.0.0",
"old_htmlpage":"ENAS5281_8.0.0.0",
"new_id":"69",
"new_nametree":"Glossary",
"new_numtree":"8.0.0.0",
"new_htmlpage":"ENAS5281_8.0.0.0"
}
]